Much choice, much confusion: Treating basal cell carcinoma
A partir d'une revue systématique de la littérature publiée jusqu'en mai 2018 (40 essais cliniques et 5 études non randomisées), cette méta-analyse compare l'efficacité, du point de vue notamment du taux de récidive, et la sécurité de différents traitements d'un carcinome basocellulaire primitif (résection, curetage, radiothérapie, cryothérapie, diathermie, photothérapie dynamique, imiquimod, 5-fluorouracile, ...)
In the United States, the number of newly diagnosed cases of nonmelanocytic skin cancer, which includes both basal cell carcinoma (BCC) and squamous cell carcinoma, is reaching epidemic proportions (1, 2). An analysis of the National Ambulatory Medical Care Survey database showed that between 1995 and 2007, office visits related to nonmelanocytic skin cancer increased 70% to 1660 visits per 100 000 person-years (3). From a health economics perspective, the annual medical cost of treating nonmelanocytic skin cancer is $4.8 billion, representing a 74% increase over the past decade (4). Although most cases of BCC are curable and are localized to the skin, they cause significant suffering and in rare cases even death, particularly in frail populations, such as elderly and immunosuppressed persons.
Annals of Internal Medicine , éditorial, 2017